Lipoxen Share Discussion Threads

[daytraders] 02/9/2011 18:57

Bit confused here, why would we take up the offer of placing shares at 11p, when we can just buy now at just over 8p and save almost 40% straight away ? very confused here.

[123asd] 20/8/2011 12:05

sicilian_ken - have you read the 4th August RNS? If you have, you will know that, despite the Russians taking a 30% (after dilution) stake in LPX, there will be legal safeguards in the agreement for its successor Xenetic's independence. The whole purpose of this move by Lipo is to accelerate orphan drugs to market, and this deal looks to promote a symbiotic relationship, since the Russian's need LPX's technology and patents. Of course there are risks, but in my opinion it is unhelpful, if not downright disingenuous, to make inflammatory statements such as you make above.

[buywell2] 20/8/2011 11:34

Tell Baxter Healthcare ..... hasn't stopped them

[sicilian_kan] 19/8/2011 20:16

bw2, I suggest you read Anna Politkovskaya's "Putin's Russia" (bar Chapter 2 which is a little tedious). If you do, you wouldn't touch any company connected to a Russian company with a barge pole.

[buywell2] 18/8/2011 11:20

''SynBio is a newly-formed Russian company whose majority shareholder will be the multi-billion dollar Russian state-owned nanotechnology investment company, Russian Corporation of Nanotechnologies (www.Rusnano.com). ''




Rusano own 40% of SynBio

SynBio own 30% of Lipoxen

Therefore the Russian State own 12% of Lipoxen

I have no problem with this .... why ?

1. It shows that the state of Russia think that Lipoxen Technology/platforms are good.

2. It bodes well for 'fast track' development of Lipoxen platforms/technologies regarding certain drugs which have not been progressing as fast as was expected.

3. It also bodes well for new fast track development of cancer related drugs , the IP and technology that has been gained through the recent German acquisition.

4. Since the Russian State own 12% of Lipoxen through their 40% stake of SynBio it follows that Lipoxen will be looked upon favorably by them regarding future drug developments/requirements .

The rationale behind the above is that Russia has embarked upon a policy of NOT paying the west for overly expensive developed drugs. Instead it is going to make it's own 'in-house' ..... firstly for it's own requirements .... but then secondly to sell to the west to make a profit.

Lipoxen effectively has the Russian State as a partner/backer.

[buywell2] 13/8/2011 10:10

Like I said ....Lipoxen has been chosen by the Russian State , as a vehicle to develop innovative drugs for their use , and then to sell to the rest of the world for profit.

''It has attracted investment from the government-owned investment company Rusnano, which will have a 41.4% holding and other Russian firms involved include Cryonix and Pharmsynthez.''

''The lead R&D partner for the project is the UK's Lipoxen''




Russian firms set up $113 million biotech venture
World News | August 09, 2011
Bookmark and Share


Kevin Grogan

Russian firms set up $113 million biotech venture

Several Russian companies have linked up to establish a joint venture designed to develop innovative treatments in the country.

The SynBio project has been initiated by the Human Stem Cells Institute (HSCI), Russia's leading biotechnology company, which will have a 28.1% stake in the venture. It has attracted investment from the government-owned investment company Rusnano, which will have a 41.4% holding and other Russian firms involved include Cryonix and Pharmsynthez.

The lead R&D partner for the project is the UK's Lipoxen, which is in the process of merging with Germany's SymbioTec. SynBio will focus on developing treatments based on three technological platforms, ie it will look at drugs engineered from cell-based technologies for the treatment of chronic diffuse liver disease, plus treatments based on the human nuclear protein histone H1 for cancer and other diseases.
Related Links
Pfizer signs drug pact with Russia s ChemRar AstraZeneca ups investment in Russia Russians overestimate their state of health study

Thirdly, SynBio will focus on "sustained-release drugs using polysialic acid", ie 'biobetters' for the treatment of diabetes, Alzheimer's, chronic kidney disease and a number of other conditions. The total budget for the project over the next four years amounts to around 3.22 billion roubles, roughly $113 million.

HSCI general director Artur Isaev said "it is difficult to overstate the importance" of the JV because "for the first time a Russian company is acting as the initiator of an international M&A project in the biotech sector to serve both the Russian and global markets". He added that Synbio is "an excellent example of how the government's programme for innovative development of the Russian pharmaceutical sector can be implemented".

Links

www.synbio-pharma.com
startfwww://www.hsci.ru

[123asd] 10/8/2011 07:51

There are synergies for both sides, which is why the deal is being done. This is made clear both by last week's RNS from LPX, and by this, taken from the 3i thread:




Several Russian companies have linked up to establish a joint venture designed to develop innovative treatments in the country.

The SynBio project has been initiated by the Human Stem Cells Institute (HSCI), Russia's leading biotechnology company, which will have a 28.1% stake in the venture. It has attracted investment from the government-owned investment company Rusnano, which will have a 41.4% holding and other Russian firms involved include Cryonix and Pharmsynthez.
The lead R&D partner for the project is the UK's Lipoxen, which is in the process of merging with Germany's SymbioTec. SynBio will focus on developing treatments based on three technological platforms, ie it will look at drugs engineered from cell-based technologies for the treatment of chronic diffuse liver disease, plus treatments based on the human nuclear protein histone H1 for cancer and other diseases.
SynBio will focus on "sustained-release drugs using polysialic acid", ie 'biobetters' for the treatment of diabetes, Alzheimer's, chronic kidney disease and a number of other conditions. The total budget for the project over the next four years amounts to around 3.22 billion roubles, roughly $113 million.
HSCI general director Artur Isaev said "it is difficult to overstate the importance" of the JV because "for the first time a Russian company is acting as the initiator of an international M&A project in the biotech sector to serve both the Russian and global markets". He added that Synbio is "an excellent example of how the government's programme for innovative development of the Russian pharmaceutical sector can be implemented".

[the_doctor] 10/8/2011 07:23

'It would appear that Lipoxen has been chosen as the vehicle to develop/acquire the new drugs that Russia are in dire need of.'

no offence buywell, but that's really just nonsense

If you have GCSF for example, with cheaper biosimilar versions on their way
1. you have no dire need
2. longer half-life versions would not be what they want
3. there would be a much better solution

The Russian organisation is investing because most likely, it thinks the technology and products are promising/ wants to use the tech
[NOTE: nothing negative there, so dont go deramping!]

- thanks dahmmy

[dahmmy] 09/8/2011 23:55

Doc

Amber trust /ephag/pharmsynthez had / have connections with angel biotechnology...
They still have a director on angels board.

Angels biggest customer is a Russia pharmaceutical called materia medica.

LPX have a contract with angelbio for GCSFs

[buywell2] 08/8/2011 17:48

It would appear that Lipoxen has been chosen as the vehicle to develop/acquire the new drugs that Russia are in dire need of.

[the_doctor] 06/8/2011 11:43

Pharmsynthez has or had something to do with Angel Bio I think

[123asd] 06/8/2011 11:15

Here's a better translation of that article in Russian:

"Pharmsynthez" acquires "SinBio"

"Pharmsynthez" acquired 100% of "SinBio." Change of ownership recorded February 24, 2011

Shareholders of Open Society "Institute of Human Stem Cells" (HSCI), met March 17, 2011 to discuss property contribution to the authorized capital of "SinBio" project with the State Corporation of Nanotechnologies ("Rosnano"). The purpose of this transaction is the initial consolidation of the assets associated with the development and introduction of new drugs in preparation for the joint project.

Alienable property contributed to a contribution to charter capital, "SinBio" to include intangible assets HSCI relating to intellectual property, and owned a stake in the HSCI SymbioTec GmbH (Germany). Total market value of assets disposed of by the board of directors determined on the basis of the evaluation report and of 506.944 million rubles. In accordance with the revaluation produced, these assets will be placed on the balance of "HSCI" on the new value.

As previously reported, the supervisory board of "Rosnano" approved the participation of corporations in the investment project, which is an observer HSCI. The project will develop, manufacture and introduce nine drugs, using nanocomposite materials. The Russian and world market is expected to take three innovative products based on histone proteins for the treatment of acute leukemia and cardiovascular disease. All preparations of the project are currently undergoing various stages of preclinical and clinical trials in Russia and Europe. The project also involved of "Pharmsynthez."

The company "Pharmsynthez" was founded in 1996 to develop new drugs and their delivery into the body, as well as innovative technologies for drug ingredients. Along with the finished product company based on the modern scientific-industrial complex and produces active pharmaceutical substances. The main owner of "Farmsintez" (75% of the equity) is the Amber Trust - an international fund established to invest in Russia and the Baltic countries. The remaining shares belongs to the chairman of the board of directors "Farmsintez" Dmitriy Genkin. The Company sells in Russia and CIS 4 own original medicinal products. At the present time "Pharmsynthez" is developing three innovative drug class BioBetters and three therapeutic vaccines.

Net profit of "Farmsintez" under RAS for the first 9 months of 2010 amounted to 8.405 mln. against 11.542 million rubles. loss a year earlier. Proceeds of "Farmsintez" for the period increased by 73,8% - to 180.6 million rubles.

[buywell2] 06/8/2011 10:30

''Artur Isaev, general director of the Human Stem Cells Institute: "It would be difficult to over-estimate the importance of today's events for us and our partners. This is the first time that a Russian company has initiated a M&A in the biotechnology sector to serve the Russian and global markets. The project intends to introduce a number of innovative drugs that will bring real progress in the treatment of socially significant diseases. Our project is an excellent example of how the government's program for innovative development of the Russian pharmaceutical sector can be implemented."

Note


I would not be suprised to see Lipoxen involved with more state backed acquisitions

[buywell2] 06/8/2011 10:23

Note my previous comment about Lipoxen now having the weight of the Russian Government behind it ................. I think the numbers mentioned might be enough to get the products to market.


RUSNANO Signs Investment Agreement for the SynBio Innovative Pharmaceuticals Project
Moscow, Russia | Posted on August 5th, 2011

The partners have established limited liability company SynBio to carry out the project, which has a total budget of 3.2 billion rubles. Of that sum, RUSNANO will co-invest up to 1.3 billion rubles. The other founders will co-invest up to 1.9 billion rubles in the form of monetary resources, intellectual property rights, and shareholding in their own and subsidiary companies. The investment period will be four years, and the project is slated to run seven.

The SynBio project will develop and launch nine pharmaceutical products for Russian and international markets. The medicines are based on three technological platforms:

stem cell technologies for treatment of chronic diffuse liver disease (the Gemacell platform)
intranuclear human protein histone H1 for treatment of cancers and other diseases (the Histone platform)
sustained-release drugs using polysialic acid-biobetters for treatment of diabetes mellitus, Alzheimer's disease, chronic kidney disease, and other illnesses (the PolyXen® platform).

Biobetters resemble biotech pharmaceuticals that already exist in the market, and they differ in that they surpass the biotech preparations by certain characteristics, such as effectiveness.

All the medicines in the project are currently undergoing pre-clinical tests or clinical trials in research laboratories in Russia and Europe. All the pharmaceuticals developed within the project are expected to be sold in the Russian and international markets. Sales of SynBio's drugs in 2015 are forecasted at 700 million rubles.

"Two facilities will be established for commercial production of the innovative medicines, one each in Leningrad and Moscow oblasts," explained Olga Shpichko, RUSNANO managing director. "Manufacturing will be set up jointly with our German and British partners. We regard this as a step toward entering the international pharmaceuticals market."

Artur Isaev, general director of the Human Stem Cells Institute: "It would be difficult to over-estimate the importance of today's events for us and our partners. This is the first time that a Russian company has initiated a M&A in the biotechnology sector to serve the Russian and global markets. The project intends to introduce a number of innovative drugs that will bring real progress in the treatment of socially significant diseases. Our project is an excellent example of how the government's program for innovative development of the Russian pharmaceutical sector can be implemented."

####

About RUSNANO
RUSNANO was founded in March 2011 as an open joint stock company through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO's mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. Anatoly Chubais is CEO and chairman of the Executive Board of RUSNANO.

Work to establish nanotechnology infrastructure and training for nanotechnology specialists, formerly conducted by the Russian Corporation of Nanotechnologies, has been entrusted to the Fund for Infrastructure and Educational Programs, a non-commercial fund also established through reorganization of the Russian Corporation of Nanotechnologies.

OJSC HSCI (Human Stem Cells Institute, www.hsci.ruNew Window) is a Russian biotech company founded in 2003. The main focus of HSCI is scientific research and development as well as commercialization and marketing of innovative proprietary products and services arising from cell-based, gene and post-genome technologies. HSCI owns the largest personal storage repository of cord blood stem cells in Russia-Gemabank.

At present HSCI is in the process of registering the first gene-therapy drug in Russia, Neovasculgen (for treatment of ischemia of the lower limbs), is receiving approval for clinical trials of the first cell-based drug Gemacell (for treatment of ischemic heart disease and cirrhosis) and is beginning to market a comprehensive set of services for individual skin regeneration-SPRS therapy (based on a technology approved by the Russian health authorities for applying autologous dermal fibroblasts to correct the effects of aging and skin defects). The company is also in the final stages of readying for the launch a multifaceted project of HSCI and RUSNANO to develop and produce new unique medicines for the Russian and international markets (the SynBio project).

In December 2009 the Humans Stem Cells Institute made an initial public offering on MICEX (ticker symbol: ISKJ), becoming the first biotech company in Russia to go public. The beginning of trading of HSCI shares also marked the opening of the exchange's Market for Innovations and Investments (MICEX MII), a platform for the innovation and growth companies sector created in cooperation with RUSNANО.

[buywell2] 06/8/2011 10:06

Lipoxen in transforming Russian deal

05/08/2011 Robert Tyerman


Russian pharmaceutical player Dmitry Genkin's SynBio company is paying £12.2 million for 30 per cent of drug discoverer Lipoxen (LPX). In a series of transformational deals, SynBio is paying a premium 11p a share for a placing by AIM-quoted Lipoxen, which is also issuing premium-priced shares and warrants to major shareholder Serum Institute of India (SIL) and proposing to change its name from Lipoxen to Xenetic Biosciences.

After raising £14.4 million from SynBio, SIL and a hoped-for £1.95 million from an open offer to shareholders, London-based Lipoxen says it intends to buy German-registered leukaemia specialist SymbioTech, where a Genkin-controlled company is a significant shareholder, for £8.8 million in shares. Lipioxen/Xenetic will also licence six of its product candidates to SynBio in Russia and regain from SIL development rights to 14 drug candidates.

Scott Maguire, chief executive officer of Lipoxen, argues these deals 'will afford the company independence as a speciality drug developer with high-value orphan drug product candidates which have shorter-term market launch potential.' Investors have reacted coolly and Lipoxen shares, which hit 75p nine years ago, are 0.13p off today at 8.75p, valuing the company at £15 million.

They have speculative potential.


Note

Dr Dmitry D Genkin
Non-executive Director

Dr Dmitry Genkin joined Lipoxen as a non-executive Director in 2000.

He has the Russian equivalent of an MD in Internal Therapy and has attended training courses in drug delivery at The School of Pharmacy, University of London (1992) and the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm (1992-1993).

Dmitry was formerly Chief Executive Officer of ASGL Research Laboratories ZAO, a company which he founded in 1994 to run drug development programmes focusing on viral and cancer diseases. He also served as executive Chairman of Pharmavit OAO and Scientific Director of Pharmavit Holding ZAO. Dmitry is currently a partner and director of FDS Pharma.

[buywell2] 06/8/2011 09:53

123asd

That link is in Russian,

ОАО; "Фаl8;мс 80;нт
077;з" при;обl8;ел 86; 100% ООО; "Сиl5;Би 86;". В мат;ерl0;ал 72;х "Фаl8;мс 80;нт
077;за" гов;орl0;тс03;, что; изм;енk7;ни03; пра;в соб;стk4;ен 85;ос
090;и зар;егl0;ст 88;ир
086;ваны 24 фев;раl3;я 2011 г.

Акц;иоl5;ер 99; ОАО; "Инl9;ти 90;ут ств;олl6;вы 93; кле;тоl2; чел;овk7;ка" (ИСi0;Ч) на соб;раl5;ии 17 мар;та 2011 г. обс;удn3;т иму;щеl9;тв 77;нн
099;й взн;ос в уст;авl5;ый кап;итk2;л ООО; "Сиl5;Би 86;" в рам;каm3; про;екm0;а с гос;удk2;рс 90;ве
085;ной кор;поl8;ац 80;ей нан;отk7;хн 86;ло
075;ий ("Ро 89;на
085;о"). Цел;ью дан;ноl1; сде;лкl0; явл;яеm0;ся пер;воl5;ач 72;ль
085;ая кон;соl3;ид 72;ци
103; акт;ивl6;в, свя;заl5;ны 93; с раз;раk3;от 82;ой и вне;дрk7;ни 77;м нов;ых лек;арl9;тв 77;нн
099;х пре;паl8;ат 86;в, в рам;каm3; под;гоm0;ов 82;и к реа;лиk9;ац 80;и сов;меl9;тн 86;го про;екm0;а.

Отч;ужk6;ае 84;ое иму;щеl9;тв 86;, вно;сиl4;ое в кач;есm0;ве вкл;адk2; в уст;авl5;ый кап;итk2;л "Сиl5;Би 86;", вкл;ючk2;ет нем;атk7;ри 72;ль
085;ые акт;ивm9; ИСК;Ч, свя;заl5;ны 77; с инт;елl3;ек 90;уа
083;ьной соб;стk4;ен 85;ос
090;ью, а так;же при;наk6;ле 78;ащ
091;ю ИСК;Ч дол;ю в ком;паl5;ии SymbioTec GmbH (Геl8;ма 85;ия). Общ;ая рын;очl5;ая сто;имl6;ст00; отч;ужk6;ае 84;ог
086; иму;щеl9;тв 72; опр;едk7;ле 85;а сов;етl6;м дир;екm0;ор 86;в на осн;овk2;ни 80; отч;етk2; об оце;нкk7; и сос;таk4;ля 77;т 506,944 млн;. руб;. В соо;твk7;тс 90;ви
080; с про;изk4;ед 77;нн
086;й пер;еоm4;ен 82;ой, пер;ечl0;сл 77;нн
099;е акт;ивm9; буд;ут пос;таk4;ле 85;ы на бал;анl9; ОАО; "ИСi0;Ч" по нов;ой сто;имl6;ст 80;.

Как; соо;бщk2;ло 89;ь ран;ее, наб;люk6;ат 77;ль
085;ый сов;ет "Роl9;на 85;о" одо;брl0;л уча;стl0;е кор;поl8;ац 80;и в инв;есm0;иц 80;он
085;ом про;екm0;е, наб;люk6;ат 77;ле
084; кот;орl6;го явл;яеm0;ся ИСК;Ч. В рам;каm3; про;екm0;а пла;ниl8;уе 90;ся раз;раk3;от 82;а, про;изk4;од 89;тв
086; и вне;дрk7;ни 77; 9 лек;арl9;тв 77;нн
099;х пре;паl8;ат 86;в, исп;олn0;зу02;щи
093; нан;окl6;мп 86;зи
090;ные мат;ерl0;ал 99;. На рос;сиl1;ск 80;й и мир;овl6;й рын;ок пре;дпl6;ла 75;ае
090;ся выв;есm0;и 3 инн;овk2;ци 86;нн
099;х пре;паl8;ат 72; на осн;овk7; бел;коk4;-ги
089;тонов для; леч;енl0;я ост;роk5;о лей;коk9;а и сос;удl0;ст 99;х заб;олk7;ва 85;ий. Все; пре;паl8;ат 99; про;екm0;а в нас;тоn3;ще 77; вре;мя про;хоk6;ят раз;лиm5;ны 77; ста;диl0; док;лиl5;ич 77;ск
080;х и кли;ниm5;ес 82;их исс;леk6;ов 72;ни
081; в Рос;сиl0; и Евр;опk7;. В про;екm0;е так;же уча;стk4;уе 90; ОАО; "Фаl8;мс 80;нт
077;з".

Ком;паl5;ия "Фаl8;мс 80;нт
077;з" осн;овk2;на в 1996 г. Зан;имk2;ет 89;я раз;раk3;от 82;ой нов;ых лек;арl9;тв 77;нн
099;х пре;паl8;ат 86;в и мет;одl6;в их дос;таk4;ки в орг;анl0;зм, а так;же инн;овk2;ци 86;нн
099;х тех;ноl3;ог 80;й пол;учk7;ни03; инг;реk6;ие 85;то
074; лек;арl9;тв 77;нн
099;х сре;дсm0;в. Нар;ядm1; с гот;овm9;ми пре;паl8;ат 72;ми ком;паl5;ия на баз;е сов;реl4;ен 85;ог
086; нау;чнl6;-пр
086;изводственн;огl6; ком;плk7;кс 72; про;изk4;од 80;т и акт;ивl5;ые фар;маm4;ев 90;ич
077;ские суб;стk2;нц 80;и. Осн;овl5;ым вла;деl3;ьц 77;м "Фаl8;мс 80;нт
077;за" (75% акц;иоl5;ер 85;ог
086; кап;итk2;ла) явл;яеm0;ся Amber Trust - меж;дуl5;ар 86;дн
099;й фон;д, учр;ежk6;ен 85;ый для; инв;есm0;ир 86;ва
085;ия в Рос;сиn2; и стр;анm9; Бал;тиl0;. Ост;алn0;на03; дол;я при;наk6;ле 78;ит пре;дсk7;да 90;ел
102; сов;етk2; дир;екm0;ор 86;в "Фаl8;мс 80;нт
077;за" Дми;трl0;ю Ген;киl5;у. Ком;паl5;ия реа;лиk9;уе 90; на рын;ке Рос;сиl0; и СНГ; 4 соб;стk4;ен 85;ых ори;гиl5;ал00;ны
093; лек;арl9;тв 77;нн
099;х пре;паl8;ат 72;. В нас;тоn3;ще 77; вре;мя "Фаl8;мс 80;нт
077;з" осу;щеl9;тв 83;яе
090; раз;раk3;от 82;у тре;х инн;овk2;ци 86;нн
099;х лек;арl9;тв 77;нн
099;х пре;паl8;ат 86;в кла;ссk2; BioBetters и тре;х тер;апk7;вт 80;че
089;ких вак;циl5;.

Чис;таn3; при;быl3;ь "Фаl8;мс 80;нт
077;за" по РСБ;У за 9 мес;яцk7;в 2010 г. сос;таk4;ил 72; 8,405 млн;. руб;. про;тиk4; 11,542 млн;. руб;. убы;ткl6;в год;ом ран;ее. Выр;учl2;а "Фаl8;мс 80;нт
077;за" за отч;етl5;ый пер;иоk6; уве;лиm5;ил 72;сь на 73,8% - до 180,6 млн;. руб;.


Translation thus far is


Open Society " Фар;мсl0;нт 77;з " were got with 100 % of LLC " Син;Биl6; ". In materials "Фаl8;мс 80;нт
077;за" it is spoken, that variations of the property rights are registered on February, 24th, 2011

Shareholders of Open Society " College ств;олl6;вы 93; cells of the person " (ИСi0;Ч) at assembly on March, 17th, 2011 will discuss a property payment in уст;авl5;ый the capital of LLC " Син;Биl6; " within the limits of the project with the state corporation нан;отk7;хн 86;ло
075;ий ("Ро 89;на
085;о"). Objective of the given deal is initial consolidation of the actives connected with development and introduction of new medical products, within the limits of preparation for realization of the joint project.

The alienated property, вно;сиl4;ое as the contribution in уст;авl5;ый the capital "Сиl5;Би 86;", includes the non-material actives ИСК;Ч connected with intellectual property, as well as belonging ИСК;Ч a fraction in companies SymbioTec GmbH (Germany). The general market cost of alienated property is certain by board of directors on the basis of the report on an assessment and makes 506,944 million rbl. According to the made reassessment, the listed actives will be put on balance of Open Society " ИСК;Ч " at new cost.

As it was informed earlier, supervisory council " Рос;наl5;о " has approved participation of corporation in the investment project which observer is ИСК;Ч. Within the limits of the project development, manufacture and introduction of 9 medical products using нан;окl6;мп 86;зи
090;ные materials is planned. On Russian and the world market supposed deduce 3 innovative preparations on the basis of fibers-ги;стl6;но 74; for treatment sharp лей;коk9;а and vascular diseases. All preparations of the project now pass various stages док;лиl5;ич 77;ск
080;х and clinical researches in Russia and the Europe. Open Society " Фар;мсl0;нт 77;з " also participates in the project.

Company " Фар;мсl0;нт 77;з " is based in 1996 Is engaged in development of new medical products and methods of their delivery in an organism, as well as innovative technologies of reception of components of medical products. Alongside with ready preparations the company on the basis of a modern research-and-production complex makes also active pharmaceutical substances. The basic owner "Фаl8;мс 80;нт
077;за" (75 % of the share capital) are Amber Trust - the international fund founded for investment to Russia and the Baltics. Other fraction belongs to chairman of board of directors " Фар;мсl0;нт 77;за " Dmitry Genkin. The company realizes in the market of Russia and the CIS own 4 original medicinal preparations. Now "Фаl8;мс 80;нт
077;з" carries out development of three innovative medical products of class BioBetters and three therapeutic vaccines.

The net profit "Фаl8;мс 80;нт
077;за" on РСБ;У for 9 months 2010 has made 8,405 million rbl. against 11,542 million rbl. of losses year earlier. The proceeds "Фаl8;мс 80;нт
077;за" have over the reporting period increased for 73,8 % - up to 180,6 million rbl.


Here is another translation from another website

Open Society " Фар;мсl0;нт 77;з " were got with 100 % of LLC " Син;Биl6; ". In materials "Фаl8;мс 80;нт
077;за" it is spoken, that variations of the property rights are registered on February, 24th, 2011

Shareholders of Open Society " College ств;олl6;вы 93; cells of the person " (ИСi0;Ч) at assembly on March, 17th, 2011 will discuss a property payment in уст;авl5;ый the capital of LLC " Син;Биl6; " within the limits of the project with the state corporation нан;отk7;хн 86;ло
075;ий ("Ро 89;на
085;о"). Objective of the given deal is initial consolidation of the actives connected with development and introduction of new medical products, within the limits of preparation for realization of the joint project.

The alienated property, вно;сиl4;ое as the contribution in уст;авl5;ый the capital "Сиl5;Би 86;", includes the non-material actives ИСК;Ч connected with intellectual property, as well as belonging ИСК;Ч a fraction in companies SymbioTec GmbH (Germany). The general market cost of alienated property is certain by board of directors on the basis of the report on an assessment and makes 506,944 million rbl. According to the made reassessment, the listed actives will be put on balance of Open Society " ИСК;Ч " at new cost.

As it was informed earlier, supervisory council " Рос;наl5;о " has approved participation of corporation in the investment project which observer is ИСК;Ч. Within the limits of the project development, manufacture and introduction of 9 medical products using нан;окl6;мп 86;зи
090;ные materials is planned. On Russian and the world market supposed deduce 3 innovative preparations on the basis of fibers-ги;стl6;но 74; for treatment sharp лей;коk9;а and vascular diseases. All preparations of the project now pass various stages док;лиl5;ич 77;ск
080;х and clinical researches in Russia and the Europe. Open Society " Фар;мсl0;нт 77;з " also participates in the project.

Company " Фар;мсl0;нт 77;з " is based in 1996 Is engaged in development of new medical products and methods of their delivery in an organism, as well as innovative technologies of reception of components of medical products. Alongside with ready preparations the company on the basis of a modern research-and-production complex makes also active pharmaceutical substances. The basic owner "Фаl8;мс 80;нт
077;за" (75 % of the share capital) are Amber Trust - the international fund founded for investment to Russia and the Baltics. Other fraction belongs to chairman of board of directors " Фар;мсl0;нт 77;за " Dmitry Genkin. The company realizes in the market of Russia and the CIS own 4 original medicinal preparations. Now "Фаl8;мс 80;нт
077;з" carries out development of three innovative medical products of class BioBetters and three therapeutic vaccines.

The net profit "Фаl8;мс 80;нт
077;за" on РСБ;У for 9 months 2010 has made 8,405 million rbl. against 11,542 million rbl. of losses year earlier. The proceeds "Фаl8;мс 80;нт
077;за" have over the reporting period increased for 73,8 % - up to 180,6 million rbl.




If anyone can translate better please post it

Lipoxen now seems to have the weight of the Russian Government behind it .... a bit better than the EU at the moment methinks

''As it was informed earlier, supervisory council " Рос;наl5;о " has approved participation of corporation in the investment project which observer is ИСК;Ч. Within the limits of the project development, manufacture and introduction of 9 medical products using нан;окl6;мп 86;зи
090;ные materials is planned.''

[the_doctor] 05/8/2011 14:54

drewz, if you dont like it, tell buywell to stop deliberately deramping my stocks

[drewz] 05/8/2011 13:56

'the_doctor',

if you will not stop your deranged masturbating on this thread, then you will have to be straight-jacketed and gagged!

You can be the thread's gimp.

the_doctor - 5 Aug'11 - 11:41 - 930 of 931 (Filtered)

the_doctor - 5 Aug'11 - 11:50 - 931 of 931 (Filtered)

[the_doctor] 05/8/2011 11:50

'Our new acquisition already has products ready to go into Phase 3 trials .... so maybe a Russian partner coming soon ?'

why would they sell out just before partnering?

who is going to fund the PIII trials?

Why would Lipoxen buy a company that has virtually nothing in common with its existing business - doesnt make sense.
IMO it was just a way of getting finance in


'will utterly transform the bio-pharmaceuticals group'

why would you utterly transform a good business?


Who owned Symbiotec?
Synbio is investing £12m
Does it get most of that back through the £8m acquisition price?

Seems an elaborate way of undertaking a £2m open offer
That'll have to be at a discount.
6p?

33m shares bought at the open offer price potentially
A further massive overhang to clear!
IMO this is going nowhere but down

- your call buywell. I asked you to stop deramping

[the_doctor] 05/8/2011 11:41

Buywell, you just couldnt resist deramping some more, could you.
deliberately trying to provoke me by deramping on several of my stocks with silly comments AGAIN
What is your problem?

So, as promised:


FALLS THROUGH THIS LEVEL AND IT'S DOWN TO 6p

10s of millions of new shares set to be dumped and a massive overhang

Think - if deals were close, would Lipoxen not have waited?
if the tech was good, why invest in a random company?
Seems odd to me.




OH and LOOK

[buywell2] 05/8/2011 11:29

Thanks

will do

[123asd] 05/8/2011 10:25

buywell - this is in Russian, but Google will do a fairly good job. It gives some background to Farmsintez's takeover of "SinBio".

[buywell2] 05/8/2011 10:03

Our new acquisition already has products ready to go into Phase 3 trials .... so maybe a Russian partner coming soon ?

From SymbioTec

Product

ONCOHIST is the first innate human cancer drug. The active pharmaceutical ingredient is a small protein of human origin which destroys cancer cells...


Salient Features
• completely new therapeutic concept
• high medical demand
• wide range of indications
• toxicity and immunogenicity close to none
• strong patent portfolio
• high marketing potential

Strategies of Development
Currently our studies focus on the large-scale production of recombinant human histone H1 derivatives for clinical studies of cancer. SymbioTec has developed its own biotechnological process to produce ONCOHIST, a derivative of human histone H1, which is provided by a bio-pharmaceutical contract-manufacturer in GMP quality for clinical studies. Acute myeloid leukemia (AML) was the first clinical indication to be chosen.

A pilot clinical Phase I/II study with AML patients has been conducted in the Saarland University's hospital Homburg/Saar and proved that our drug ONCOHIST is well tolerated and gave already clear indications of clinical effects.

Clinical studies including other indications in the field of neoplastic diseases are envisaged. SymbioTec welcomes strategic alliances with internationally operating cooperation partners for the opening of markets in its central area, tumour therapy, as well as for the development of the diagnostic potential of histone-related medicaments.

IP looks to have been sorted

Intellectual Property

Patents

Our patent portfolio covers the application of histones and its derivatives as therapeutics for tumor and infectious diseases. Our intellectual property rights cover a much wider field of potential applications, and we are continually extending the company's patent portfolio aiming at personalised treatment and diagnostics.
SymbioTec owns about 40 patents in 10 patent families.